A few days ago, the innovative tumor immune drug atelizumab (Taishengqi) combined with bevacizumab ("T+A" combination therapy) liver cancer indications was officially launched, bringing new treatment options for Chinese patients with advanced liver cancer .
Taishengqi immune combination therapy liver cancer indications Beijing listing meeting
In China, liver cancer prevention and treatment is an important topic of national health.
China's population accounts for approximately 18.4% of the global population, but each year new cases and deaths of liver cancer account for nearly half of the world.
Due to the insidious onset and rapid progress of liver cancer, most of the liver cancer patients in my country are in the middle and late stages when they are first diagnosed, and the diagnosis rate of early patients is less than 20%, which is far behind the developed countries.
For patients with advanced liver cancer, especially unresectable hepatocellular carcinoma, systemic treatment options are limited. The overall survival of patients has not been greatly improved for more than ten years. There is an urgent need for effective innovative drugs and treatment programs to break through the dilemma.
Nowadays, the approval and marketing of liver cancer indications for atelizumab combined with bevacizumab ("T+A" combination therapy) is a breakthrough in the field of liver cancer treatment.
The main basis for this approval is the phase III clinical trial IMbrave150, which includes an analysis of 194 patients in the Chinese subgroup.
The results of the study confirmed that, compared with standard treatment, the "T+A" combination therapy can reduce the risk of death and disease progression in patients with liver cancer and improve the quality of life of patients.
This clinical trial is the first phase III clinical study for the first-line treatment of advanced hepatocellular carcinoma in recent years. The IMbrave150 study has achieved excellent positive results, suggesting that the atilizumab combined with bevacizumab regimen is inoperable for advanced first-line treatment The survival benefit of patients is significant, which brings more hope for liver cancer patients.
The success of this innovative therapy is mainly due to its unique mechanism of action. Professor Li Qiang, an expert in the Department of Hepatobiliary Oncology, Tianjin Medical University Cancer Hospital, explained, “The'T+A' combination therapy combines PD-L1 immunotherapy drugs with anti-angiogenesis drugs Used together, the former is to improve immunity to kill tumors, and the latter is to block tumor blood vessels to inhibit tumor growth and metastasis. First, the necessary metabolic pathways of tumor cells are interrupted, and then antibodies are used to attack tumor cells, flanking both sides to achieve a perfect combination. Therapeutic effect."
"The successful trial results of the'T+A' combination therapy will lead the development of comprehensive treatment of liver cancer." Professor Li Qiang said, "Each patient's disease situation is different, and individualized precise treatment is required. When there is radiotherapy and chemotherapy When using a series of treatments such as immunotherapy, targeted therapy, anti-angiogenic drugs, etc., doctors need to consider the order of use of each therapy, the length of use, and other issues to formulate a suitable comprehensive treatment strategy."
In addition to the introduction of new treatment methods, early detection, early diagnosis, and early treatment of tumors are required to truly improve the cure rate of patients.
Professor Li Qiang said, “The prevention and treatment of liver cancer advocates the “six early days”, that is, early prediction, early prevention, early detection, early diagnosis, early treatment, and early cure. Regular physical examinations for high-risk groups are effective measures to prevent liver cancer. If the public, especially high-risk groups, Increase your vigilance against liver cancer and go for regular physical examinations. Liver cancer is not terrible."